Filing summary
Company identification: Although the request metadata names Decoy Therapeutics Inc., the supplied Form 10-Q is for Flex Pharma, Inc. It covers the quarter ended September 30, 2017; the financial statements are unaudited.
Business context and reporting period
Flex Pharma was developing FLX-787 for muscle cramps and spasticity associated with neurological conditions and selling HOTSHOT, a consumer product for exercise-associated cramps. It reported Consumer Operations and Drug Development segments. The filing describes an August 2017 U.S. Phase 2 trial of FLX-787 in motor neuron disease, an exploratory Phase 2 study in multiple sclerosis in Australia, and a CMT Phase 2 trial initiated in October 2017.
Financial performance and liquidity
- Third-quarter revenue: $413,601, down 31% from $599,074 a year earlier. Net product revenue was $407,241. The company attributed lower HOTSHOT volume partly to launch-related media coverage in 2016; it sold about 87,000 bottles versus 123,000, and offered promotions that lowered average revenue per bottle.
- Third-quarter loss: Operating loss was $9.4 million and net loss was $9.3 million, compared with $10.7 million and $10.6 million, respectively, in Q3 2016. Basic and diluted loss per share was $0.54 versus $0.65.
- Nine-month results: Revenue was $991,671, up 39% year over year; operating loss was $26.6 million and net loss was $26.4 million, versus $31.9 million and $31.6 million in 2016. Loss per share was $1.54 versus $1.96.
- Product gross margin: Approximately 63.5% in Q3 2017 (revenue less product costs, divided by revenue), versus 63.1% in Q3 2016. For the first nine months, it was approximately 62.4% versus 25.7%; the prior-year period included substantially larger inventory write-offs.
- Cash flow: Operating cash use for the first nine months was $22.1 million, compared with $25.8 million in 2016. Investing activities provided $19.8 million, primarily reflecting net maturities and sales of marketable securities. Cash and cash equivalents decreased $2.3 million to $20.2 million.
- Liquidity and debt: Cash, cash equivalents and marketable securities totaled $38.9 million at September 30, 2017; working capital was $35.6 million. The company reported no long-term debt. Management said existing resources were expected to fund its operating plan for at least 12 months from issuance; the MD&A separately projected funding into early 2019, subject to assumptions.
- Balance sheet: Total assets were $41.2 million, total liabilities $5.0 million, and stockholders’ equity $36.2 million. Accumulated deficit was $103.1 million. No significant income tax provision or benefit was recorded.
Material changes and management commentary
- For the first nine months, HOTSHOT bottle sales rose to about 222,000 from 147,000, reflecting its availability for all of 2017 to date versus a June 2016 launch. Average revenue per bottle declined to $4.47 from $4.84, which management attributed to promotions. E-commerce accounted for about 82% of nine-month revenue, down from 92%, as specialty retailer and sports-team sales increased.
- Research and development expense declined 21% year over year to $12.7 million for the first nine months, principally because prior-year development activities had ended or wound down; the reduction was partly offset by startup and production costs for U.S. FLX-787 trials. Selling, general and administrative expense declined 9% to $14.5 million, including lower stock compensation and personnel costs, partly offset by higher marketing and website spending.
- Management expected continued losses and said additional capital would be needed unless revenue becomes sufficient. It warned that financing may not be available on acceptable terms and could require delaying, reducing or discontinuing programs; equity financing could dilute shareholders.
- The company signed a Boston headquarters lease through August 2019, increasing future minimum lease payments by $933,186. It also disclosed reliance on a single HOTSHOT co-packer and certain sole-source raw-material suppliers.
Outlook, risks and unusual items
- Management expected topline results from the U.S. COMMEND ALS/MND trial and the CMT COMMIT trial in Q3 2018. The ALS study in Australia was stopped after 12 patients had been randomized because of enrollment challenges and prioritization of COMMEND.
- The filing reports November 2017 topline results from the Australian exploratory study: among eight per-protocol completers, FLX-787 showed statistically significant reductions in cramp-associated pain intensity and stiffness versus placebo. Several other outcomes were described as trends. The small sample and exploratory nature limit how broadly these results can be interpreted.
- Management also announced plans to pursue FLX-787 for dysphagia and renal-dialysis-associated cramping, with clinical development planned during 2018. These are forward-looking plans, not reported trial results.
- Inventory write-offs were $14,701 in Q3 2017 and $34,235 for the first nine months, including expiring finished goods and raw materials not expected to be used. The filing identifies clinical-trial execution, regulatory approval, commercialization, funding, intellectual property, key-person retention and product supply as material risks.
- Management concluded disclosure controls were effective at the reasonable-assurance level. No material legal proceedings or off-balance-sheet arrangements were reported.
Important facts for investors to verify
- Confirm the issuer: this supplied filing is Flex Pharma, Inc., not Decoy Therapeutics Inc.
- Track cash use, remaining runway and financing needs against management’s assumptions; the filing presents both an at-least-12-month liquidity statement and an outlook into early 2019.
- Review COMMEND and COMMIT enrollment, timelines and results, and assess the Australian study’s small per-protocol sample and exploratory findings.
- Monitor HOTSHOT sales, promotional pricing, channel mix, inventory shelf life and dependence on the single co-packer and sole-source suppliers.
- Assess whether the reported expense reductions reflect sustainable operating changes or timing, lower stock compensation and completed prior-year activities.